PubMed Health⌕ Search
Home/Archive/PubMed

PubMed · 7921532

Drug interaction studies during drug development: which, when, how?

J Kuhlmann
View original source ↗Export metadata ↓

Abstract

Drug-drug interaction studies have become an important aspect of the development process of new drugs. Since formal studies of all possible interactions are neither practicable nor suggestive, a careful selection of a limited number of drug combinations to be investigated during the development phase is indicated. Priorities should be based on the likelihood of certain combinations to occur in clinical practice as well as on risks associated with them. In the main, clinical drug interaction studies are performed during late phase II and phase III of clinical drug development. In some exceptional cases clinical interaction studies are necessary at an earlier stage of development. This counts especially for drugs with a small therapeutic range and a steep course of the dose-response curve and especially for drug interactions which may effect vital processes. For all other drugs often administered together an initial screen for pharmacokinetic and/or pharmacodynamic interactions with plasma level measurements and examinations of a possible concentration-effect relationship might be sufficient. Taking these criteria into account an interaction program for new drugs under development with different indications like cardiovascular diseases, respiratory diseases, diseases of the central nervous system as well as rheumatic diseases, metabolic diseases and infectious diseases was developed.

Explore related subjects

Dose-Response Relationship, DrugDrug InteractionsHumansPharmacokineticsClinical TrialJournal ArticleReview

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J Kuhlmann. 1994. Drug interaction studies during drug development: which, when, how?. https://pubmed.ncbi.nlm.nih.gov/7921532/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Vitamin D in the treatment of pulmonary tuberculosis.

Vitamin D was used to treat tuberculosis in the pre-antibiotic era. New insights into the immunomodulatory properties of 1alpha,25-dihydroxy-vitamin D have rekindled interest in vitamin D as an adjunct to antituberculous therapy. We describe the historical use of vitamin D in tuberculosis treatment; discuss the mechanisms by which it may modulate host response to infection with Mycobacterium tuberculosis; and review three clinical trials and ten case series in which vitamin D has been used in the treatment of pulmonary tuberculosis.

Dose-Response Relationship, Drug↗
PubMed2007

Quantitative analysis of Akt phosphorylation and activity in response to EGF and insulin treatment.

The protein kinase Akt is a critical regulator of cell function and its overexpression and activation have been functionally linked to numerous pathologies such as cancer. Previous reports regarding the mechanism-regulating Akt's activation have revealed two phosphorylation events, at threonine 308 (T308) and serine 473 (S473), as necessary for the full activation of the kinase in response to insulin. For this reason and because of the availability of phospho-specific antibodies to both T308 and S473, many studies that focus on Akt's role in governing cell function rely on the measurement of these two sites to understand changes in kinase activity. Recent evidence, however, suggests the involvement of other phosphorylation sites; for example, in Src-transformed and epidermal growth factor (EGF)-treated cells, tyrosine phosphorylation has been found important for full kinase activation. In this study, we probed the quantitative reliability of using S473 and/or T308 phosphorylation as surrogates for Akt kinase activity across diverse treatment conditions. We performed quantitative Western blots and kinase activity assays on lysates generated during a 2h time course from two cell lines treated with either EGF or insulin. From the resulting approximately 250 quantitative measurements of phosphorylation and activity, we found that both T308 and S473 phosphorylation accurately captured quantitative changes in EGF-stimulated cells, but not in insulin-stimulated cells. Moreover, in all but one condition studied, we found a tight correlation between the onset of phosphorylation and dephosphorylation for both sites, despite the fact that they do not share common kinase- or phosphatase-mediated regulation. In sum, using a quantitative approach to study Akt activation identified ligand-dependent limits for the use of T308 or S473 as proxies for kinase activity and suggests the coregulation of Akt phosphorylation and dephosphorylation.

Dose-Response Relationship, Drug↗
PubMed2006

Hormesis, epitaxy, the structure of liquid water, and the science of homeopathy.

According to the western medical establishment, homeopathy is both "unscientific" and "implausible". A short overview of its history and the methods it uses, however, easily reveals that homeopathy is a true science, fully grounded on the scientific method and on principles, such as, among others, the Arndt-Schultz law, hormesis, and epitaxy, whose plausibility has been clearly and definitely demonstrated in a number of scientific publications and reports. Through a review of the scientific literature, an explanation of the basic principles of homeopathy is proposed based on arguments and evidence of mainstream science to demonstrate that, in spite of the claims of conventional medicine, homeopathy is both scientific and plausible and that there is no reasonable justification for its rejection by the western medical establishment. Hopefully, this hurdle will be overcome by opening academic institutions to homeopathy to enlarge the horizons of medical practice, recover the value of the human relationship with the patient, and through all this, offer the sick a real alternative and the concrete perspective of an improved quality of life.

Dose-Response Relationship, Drug↗